Use of astragalus pharmaceutical composition for enhancing cancer treatment drugs

Abstract

The present invention provides a use of pharmaceutical composition for enhancing cancer treatment, which comprises an Astragalus membranaceus extract and a mannose. The pharmaceutical composition can effectively enhance the effectiveness of chemotherapy drugs, thereby reducing cancer cell viability, and for drug resistant cancers, in addition, the pharmaceutical composition can also inhibit the growth of tumor cells.

Description

Use of Astragalus pharmaceutical compositions in the preparation of drugs to enhance cancer treatment [Technical Field]

[0001] This invention provides a pharmaceutical composition in which refined Astragalus polysaccharides (r-APS) and mannose are combined and added to a chemotherapy drug, thereby enhancing the ability of the chemotherapy drug to kill cancer cells in different cancer tumor cells.

[0002] [Previous Technology]

[0003] Astragalus (also known as Huangqi) refers to the Mongolian Astragalus or Membranaceus. Specifically, it refers to the dried root of either the Mongolian or Membranaceus membranaceus subspecies (Astragalus membranaceus Bge. var. mongholicus (Bge.) Hsiao) or the Membranaceus membranaceus subspecies (A. membranaceus (Fisch.) Bge.). According to traditional pharmacology, Astragalus is used to treat chronic nephritis, proteinuria, myositis, and as an antihypertensive agent. It is also used to treat coronary heart disease, cerebral infarction, peptic ulcers (duodenal and gastric ulcers), kidney disease, and diabetes. Furthermore, several Astragalus extracts are used to treat tumors. Some studies suggest that the mechanism of action in treating tumors involves regulating immune responses (Lau, BHS, Ruckle, HCBotolazzo, T., and Lui, PD – a traditional Chinese medicine approach that inhibits the growth of renal cell carcinoma in mice).

[0004] In recent years, the components of Astragalus membranaceus have been analyzed, including monosaccharides, polysaccharides, flavonoids, amino acids, and trace elements. Among them, polysaccharides are the most abundant, and it has been confirmed that polysaccharides have therapeutic effects on diseases, especially cancer-related diseases, such as tumors (US Patent No. 5,268,467; Tang, W. Hemm, I. and Bertram, B., "Recent Developments in Antitumor Agents from Traditional Chinese Medicine", Part II, High Molecular Weight Compounds).

[0005] Malignant tumors consume far more glucose than healthy tissues to grow rapidly, making it difficult to control blood glucose levels through diet alone. The Beatson Cancer Research UK Institute states, "Tumors require large amounts of glucose to grow, so limiting the amount of glucose available to them can slow cancer progression. However, the problem is that normal tissues also need glucose, so we cannot completely remove it. Research has shown that a certain dose of mannose can block enough glucose to slow tumor growth in mice without affecting normal tissues. This is still early research, but if a perfect balance can be found in the future, mannose could enhance the effectiveness of chemotherapy in cancer patients without harming their overall health." Mannose is a hexose, present in trace amounts in human blood, and its supply is known not to come from food absorption, but primarily from glucose metabolism.

[0006] Although targeted therapies and precision medicine technologies are becoming increasingly sophisticated, the challenge of drug resistance remains a significant obstacle in cancer treatment. High-dose or long-term use of targeted chemotherapy drugs often leads to drug resistance in cancer cells, allowing them to survive and continue growing within the host, ultimately rendering chemotherapy ineffective. Chemotherapy drugs are effective in the initial stages of treatment, suppressing tumor growth. However, after a period of time, the tumor may regrow. As treatment continues, the drugs become less effective, a phenomenon known medically as drug resistance. Drug resistance not only causes cancer recurrence but also leaves patients with no effective treatment options. Therefore, reducing the side effects of chemotherapy drugs and addressing drug resistance in cancer treatment are crucial issues.

[0007] Therefore, there is an urgent need to develop an effective, safe, and drug-resistant pharmaceutical composition.

[0008] [Summary of the Invention]

[0009] To address the aforementioned issues, our research revealed that a pharmaceutical composition combining Astragalus extract and mannose, when used on patients undergoing chemotherapy, can enhance the effectiveness of chemotherapy in reducing cancer cell survival rates compared to using Astragalus extract or mannose alone. This allows patients to use only the same dose of chemotherapy drugs while simultaneously increasing the dosage of chemotherapy drugs that reduce cancer cell survival rates, thus effectively enhancing the therapeutic effect of chemotherapy.

[0010] The pharmaceutical composition of Astragalus extract and mannose of the present invention allows patients with chemotherapy drug resistance to use only the same dose of chemotherapy drugs as before, but increases the effect of chemotherapy drugs in reducing cancer cell survival rate by at least 16%. Therefore, even if patients develop drug resistance, they can still effectively enhance the therapeutic effect of chemotherapy drugs.

[0011] This invention provides the use of an Astragalus (Huangqi) pharmaceutical composition in the preparation of a drug that enhances the effect of cancer chemotherapy drugs in inhibiting the survival rate of cancer cells, wherein the Astragalus pharmaceutical composition comprises Astragalus extract and mannose.

[0012] In some embodiments of the present invention, the cancer chemotherapy drug is a chemotherapy targeted drug that is a chemotherapy targeted drug for a corresponding cancer type.

[0013] In some embodiments of the present invention, the cancer includes colorectal cancer, ovarian cancer, or lung cancer.

[0014] In some embodiments of the present invention, the chemotherapy targeted drug for the corresponding cancer includes Regorafenib, Olaparib, or Tarceva.

[0015] In some embodiments of the present invention, the effective dosage ratio of the astragalus extract and the mannose in the pharmaceutical composition is 1.5-4.5:5.5-8.5, and the concentration range of the astragalus extract and mannose composition is 0-10 mg / mL.

[0016] In some embodiments of the present invention, the pharmaceutical composition may be a tablet, pill, granule, powder, capsule or liquid.

[0017] In another embodiment of the invention, there is provided the use of an Astragalus medicinal composition in the preparation of a medicament for enhancing the inhibition of cancer cell survival by a cancer chemotherapy drug for treating drug-resistant cancer, characterized in that the Astragalus medicinal composition comprises Astragalus extract and mannose.

[0018] In one embodiment of the present invention, the cancer is a solid tumor cancer, wherein the solid tumor cancer includes colorectal cancer, ovarian cancer, and lung cancer.

[0019] In another embodiment of the invention, there is provided the use of an Astragalus pharmaceutical composition in the preparation of a medicament that enhances the effect of cancer chemotherapy drugs in inhibiting tumor cell proliferation, wherein the pharmaceutical composition comprises Astragalus extract and mannose.

[0020] In one embodiment of the present invention, the tumor cells are drug-resistant tumor cells.

[0021] In one embodiment of the present invention, the tumor cells include colorectal cancer, ovarian cancer, and lung cancer.

[0022] To achieve the above and other objectives, one or more specific embodiments of the present invention will be described below.

[0023] Other features or advantages of the present invention are described in detail with reference to embodiments and claims. [Attached Image Description]

[0024] Figure 1A shows the results of Astragalus extract (r-APS) on drug-resistant lung cancer cell line (HCC827GR cells).

[0025] Figure 1B shows the results of Astragalus extract (r-APS) and its pharmaceutical composition with mannose against the drug-resistant lung cancer cell line (HCC827GR cells).

[0026] Figure 1C shows the results of the chemotherapy drug Iressa on the lung cancer drug-resistant cell line (HCC827GR cells).

[0027] Figure 2A shows the results of Astragalus extract (r-APS) on the drug-resistant lung cancer cell line (H1975 cells).

[0028] Figure 2B shows the results of the pharmaceutical composition of Astragalus extract (r-APS) and mannose against the drug-resistant lung cancer cell line (H1975 cells).

[0029] Figure 2C shows the results of the lung cancer chemotherapy drug Tarceva on the lung cancer drug-resistant cell line (H1975 cells).

[0030] Figure 3A shows the results of Astragalus extract combined with the lung cancer chemotherapy drug Tarceva on drug-resistant lung cancer cells (H1975 cells).

[0031] Figure 3B shows the results of a pharmaceutical composition of Astragalus extract (r-APS) and mannose combined with the lung cancer chemotherapy drug Tarceva against a lung cancer resistant cell line (H1975 cells).

[0032] Figure 4A shows the results of 60-70% chemotherapy inhibition in the selection of colorectal cancer cell line (HCT116 cells).

[0033] Figure 4B shows the results of culturing colorectal cancer cell line (HCT116 cells) for 48 hours after adding Astragalus extract (r-APS).

[0034] Figure 4C shows the results of culturing colorectal cancer cell line (HCT116 cells) for 48 hours after adding a pharmaceutical composition of astragalus extract (r-APS) and mannose.

[0035] Figure 4D shows the results of culturing HCT116 colorectal cancer cell line (HCT116 cells) for 48 hours after adding Astragalus extract (r-APS) and combining it with the colorectal cancer chemotherapy drug Regorafenib.

[0036] Figure 4E shows the results of culturing HCT116 colorectal cancer cell line (HCT116 cells) for 48 hours after incorporating a pharmaceutical composition of astragalus extract (r-APS) and mannose, along with the colorectal cancer chemotherapy drug Regorafenib.

[0037] Figure 5A shows the results of 60-70% chemotherapy inhibition in ovarian cancer cell lines (OVCAR3 cells).

[0038] Figure 5B shows the results of culturing ovarian cancer cell lines (OVCAR cells) for 48 hours after adding Astragalus extract (r-APS).

[0039] Figure 5C shows the results of culturing ovarian cancer cell lines (OVCAR cells) for 48 hours after adding a pharmaceutical composition of astragalus extract (r-APS) and mannose.

[0040] Figure 5D shows the results of 48 hours of culture of ovarian cancer cell lines (OVCAR cells) after adding Astragalus extract (r-APS) and combining it with the colorectal cancer chemotherapy drug olaparib.

[0041] Figure 5E shows the results of culturing ovarian cancer cell lines (OVCAR cells) for 48 hours after incorporating a pharmaceutical composition of astragalus extract (r-APS) and mannose, combined with the colorectal cancer chemotherapy drug olaparib.

Detailed Implementation Methods

[0042] In this invention, "r-APS" refers to Astragalus membranaceus extract, and "mannose" refers to mannose.

[0043] The enhanced effect of the chemotherapy drug described in this invention is an increase of at least 16% in therapeutic efficacy.

[0044] The chemotherapy drugs described in this invention include targeted chemotherapy drugs, and the targeted chemotherapy drugs are targeted chemotherapy drugs for the corresponding cancer types.

[0045] This invention provides the use of a pharmaceutical composition for enhancing the efficacy of chemotherapy drugs in cancer treatment, comprising Astragalus membranaceus extract and mannose, wherein the weight ratio of Astragalus membranaceus extract to mannose in the pharmaceutical composition is 1.5–4.5:5.5–8.5. The effective concentration of Astragalus membranaceus extract and mannose in the pharmaceutical composition of this invention is 0–10 mg / mL. Preferably, the effective concentration of Astragalus membranaceus extract is 3 mg / mL and the effective concentration of mannose is 7 mg / mL.

[0046] This invention also provides the use of a pharmaceutical composition for enhancing or maintaining the therapeutic effect of chemotherapy drugs on drug-resistant cancers, comprising Astragalus extract and mannose, wherein the weight ratio of Astragalus extract to mannose in the pharmaceutical composition is 1.5–4.5:5.5–8.5. The effective concentration of Astragalus extract and mannose in the pharmaceutical composition of this invention is 0–10 mg / mL. Preferably, the effective concentration of Astragalus extract is 3 mg / mL and the effective concentration of mannose is 7 mg / mL.

[0047] This invention also provides a pharmaceutical composition for treating and inhibiting tumor cell proliferation, comprising Astragalus extract and mannose, wherein the weight ratio of Astragalus extract to mannose in the pharmaceutical composition is 1.5–4.5:5.5–8.5. The effective concentration of Astragalus extract and mannose in the pharmaceutical composition of this invention is 0–10 mg / mL. Preferably, the effective concentration of Astragalus extract is 3 mg / mL and the effective concentration of mannose is 7 mg / mL.

[0048] The preparation process of Astragalus extract of this invention:

[0049] (1) Take Astragalus membranaceus slices and place them in a container, add pure water to form a solution A;

[0050] (2) Heat the solution A formed in step (1) at a temperature of 80-100°C for 2-4 hours.

[0051] (3) Collect and concentrate the solution from step (2) to obtain extract A;

[0052] (4) Place the extract A from step (3) into container B, add 30-50% ethanol, stir and let it stand to precipitate, then collect the supernatant and concentrate it to obtain concentrated solution A.

[0053] (5) Add 75% to 95% ethanol to the concentrated solution A obtained in step (4), stir and let it stand to precipitate, and collect the precipitate A.

[0054] (6) The precipitate A from step (5) is dehydrated and filtered, then dissolved and precipitated with alcohol, and finally centrifuged to obtain product A, which contains Astragalus extract (r-APS).

[0055] Example 1: Effects of Astragalus Extract and Mannose on Drug-Resistant Lung Cancer Cells

[0056] This embodiment investigates the effects of Astragalus extract and mannose on drug-resistant lung cancer cells. Three experimental groups were used, and the treatments were as follows:

[0057] (1) Experimental group 1: Astragalus extract (r-APS) at different concentrations were 0.25 mg / ml, 0.5 mg / ml, 1 mg / ml, 2 mg / ml and 4 mg / ml.

[0058] (2) Experimental Group 2: The pharmaceutical composition (r-APS+mannose) of different concentrations (Astragalus extract: mannose 30%: 70%) of Astragalus extract and mannose was 0.625 mg / ml, 1.25 mg / ml, 2.5 mg / ml, 5 mg / ml and 10 mg / ml respectively.

[0059] (3) Experimental Group 3: Iressa (for HCC827GR cell line) or Tarceva (for H1975 cell line).

[0060] Test group 1, test group 2 and test group 3 were added to HCC827GR or H1975 lung cancer cell lines, respectively. After 24 hours, 48 ​​hours and 72 hours of treatment for each group, the cell viability of HCC827GR or H1975 lung cancer cell lines was tested. The results are shown in Figure 1A-1C and Figure 2A-2C.

[0061] The HCC827GR cell line is a cell line that has developed resistance to the chemotherapy drug Iressa for treating lung cancer. The results showed that test group 2 (Astragalus extract) and test group 3 (a pharmaceutical composition of Astragalus extract and mannose) had better anti-lung cancer effects (as shown in Figures 1A-1C).

[0062] The H1975 cell line is a cell line resistant to Tarceva, a drug used to treat lung cancer. The results showed that test group 3 (a pharmaceutical combination of Astragalus extract and mannose) had the best anticancer effect (as shown in Figures 2A-2C).

[0063] Example 2: The effect of a pharmaceutical composition of Astragalus extract and mannose combined with an anticancer drug on drug-resistant lung cancer cells.

[0064] This embodiment investigates the effect of a pharmaceutical composition of Astragalus extract and mannose on drug-resistant lung cancer cells. Three experimental groups were used, and the treatments were as follows:

[0065] (1) Experimental group 1: Astragalus extract (r-APS) at different concentrations were 0.25 mg / ml, 0.5 mg / ml, 1 mg / ml, 2 mg / ml and 4 mg / ml.

[0066] (2) Test group 2: The pharmaceutical composition of Astragalus extract and mannose at different concentrations (30%:70% Astragalus extract: mannose) (r-APS+mannose) was 0.625 mg / ml, 1.25 mg / ml, 2.5 mg / ml, 5 mg / ml and 10 mg / ml.

[0067] Each test group was used in combination with Tarceva (concentrations of 1.25 μM, 2.5 μM, and 5 μM, respectively) and added to the H1975 lung cancer cell line. Each group was treated for 24 hours, 48 ​​hours, and 72 hours, and the cell viability of the H1975 lung cancer cell line was measured.

[0068] The H1975 cell line is a cell line resistant to the chemotherapy drug Tarceva. The results showed that test group 1 (Astragalus extract) and test group 2 (a pharmaceutical composition of Astragalus extract and mannose combined with the chemotherapy drug Tarceva) had the best anti-cancer effect (as shown in Figures 3A-3B). That is, test group 1 (Astragalus extract) and test group 2 (a pharmaceutical composition of Astragalus extract and mannose) combined with the chemotherapy drug Tarceva had the best therapeutic effect in reversing the resistance of anti-lung cancer drugs.

[0069] Example 3: The effect of the pharmaceutical composition of the present invention on colorectal cancer

[0070] Experimental method:

[0071] First, a toxic dose test was conducted (the chemotherapy drug dose was selected so that it inhibited cell growth by 60-70% for subsequent experiments).

[0072] After seeding cells into 96-well plates, culture for 24 hours.

[0073] Different concentrations of test drugs were added, with Astragalus extract (r-APS) tested at concentrations of 0, 2, and 4 mg / ml, and the pharmaceutical composition of Astragalus extract and mannose (r-APS+mannose) tested at concentrations of 0, 5, and 10 mg / ml.

[0074] The dosage of chemotherapy drugs should be selected based on the toxicity of individual cells, with a dose between 35% and 40%.

[0075] Cell viability was tested at 48 and 72 hours after addition.

[0076] Chemotherapy synergistic effect study of Astragalus extract (r-APS) and a pharmaceutical composition of Astragalus extract and mannose (r-APS+mannose).

[0077] Cells were seeded in 96-well plates and cultured for 24 hours.

[0078] Simultaneously, cells were cultured for 48 hours with either Astragalus extract (r-APS) or a pharmaceutical combination of Astragalus extract and mannose (r-APS+mannose) and chemotherapeutic drugs. The doses of Astragalus extract (r-APS) and the pharmaceutical combination of Astragalus extract and mannose (r-APS+mannose) were selected as the four toxic doses tested. Cell viability was measured by MTS after 48 hours.

[0079] Results of toxic dose testing: As shown in Table 1, the chemotherapy drug Regorafenib at 0.01 mM can kill up to 60% of cancer cells, simulating the situation of cancer patients after taking chemotherapy drugs. Subsequent chemotherapy synergistic experiments were conducted using Astragalus extract (r-APS) and a pharmaceutical composition of Astragalus extract and mannose (r-APS+mannose). (See Figure 4A)

[0080] Table 1. Cell survival rate (%) after different concentrations of the chemotherapy drug Regorafenib killed HCT116 colorectal cancer cells.

[0081]

[0082] As shown in Table 2, colorectal cancer cells (HCT116 cells) were cultured for 48 hours after the addition of Astragalus extract (r-APS). The results showed that the use of Astragalus extract (r-APS) alone slightly promoted the growth of cancer cells, thus indicating that the use of Astragalus extract (r-APS) alone had no significant toxic effect (as shown in Figure 4B).

[0083] Table 2. Cell viability (%) of colorectal cancer cells (HCT116 cells) after 48 hours of culture with different concentrations of Astragalus extract (r-APS)

[0084]

[0085] As shown in Table 3, after HCT116 was treated with a pharmaceutical composition of Astragalus extract and mannose (r-APS+mannose) for 48 hours, the results showed that the pharmaceutical composition of Astragalus extract and mannose (r-APS+mannose) actually promoted the growth of cancer cells. Therefore, the pharmaceutical composition of Astragalus extract and mannose (r-APS+mannose) had no significant toxic effect (as shown in Figure 4C).

[0086] Table 3. Cell viability (%) of colorectal cancer cells (HCT116 cells) after 48 hours of culture with a pharmaceutical composition of different concentrations of Astragalus extract and mannose (r-APS+mannose).

[0087]

[0088]

[0089] As shown in Table 4, colorectal cancer cells (HCT116 cells) were cultured with the chemotherapy drug Regorafenib (0.01 mM) and Astragalus extract (r-APS) for 48 hours. The results showed that Astragalus extract promoted the growth of cancer cells at an effective concentration of 2 mg / mL, while it slightly inhibited the growth of cancer cells at 4 mg / mL. Therefore, it was shown that Astragalus extract (r-APS) combined with chemotherapy drugs had no significant toxic effect (as shown in Figure 4D).

[0090] Table 4. Cell survival rate (%) of colorectal cancer cells (HCT116 cells) cultured for 48 hours after adding the chemotherapy drug Regorafenib (0.01 mM) and Astragalus extract (r-APS).

[0091]

[0092] As shown in Table 5, after HCT116 was cultured for 48 hours with the addition of the chemotherapy drug Regorafenib (0.01 mM) and a pharmaceutical composition of Astragalus extract and mannose (r-APS+mannose), the results showed that when the effective dose of the pharmaceutical composition of Astragalus extract and mannose (r-APS+mannose) was 10 mg / mL, the combination with chemotherapy drugs could effectively reduce the survival rate of cancer cells. Therefore, it is shown that the combination of Astragalus extract and mannose (r-APS+mannose) with chemotherapy drugs has a significant toxic effect (as shown in Figure 4E).

[0093] Table 5. Cell viability (%) of colorectal cancer cells (HCT116 cells) cultured for 48 hours after incorporating the chemotherapy drug Regorafenib (0.01 mM) with a pharmaceutical composition of Astragalus extract and mannose (r-APS+mannose).

[0094]

[0095] The results of this experiment show that the pharmaceutical composition of Astragalus extract and mannose of this invention, when combined with chemotherapy drugs, can further reduce the survival rate of colorectal cancer cells by 16% compared with the use of drugs alone, thus effectively enhancing the therapeutic effect of chemotherapy drugs.

[0096] Example 4: The effect of the pharmaceutical composition of the present invention on ovarian cancer

[0097] Experimental method:

[0098] (1) Poisoning dose test (select the chemotherapy drug dose that has 60-70% of the ability to inhibit cell growth for subsequent tests).

[0099] (2) After seeding cells into 96-well plates, culture for 24 hours.

[0100] (3) Different concentrations of test drugs were added, with Astragalus extract (r-APS) test concentrations of 0, 2 and 4 mg / ml, and Astragalus extract and mannose pharmaceutical composition (r-APS+mannose) test concentrations of 0, 5 and 10 mg / ml, respectively.

[0101] (4) The dosage of chemotherapy drugs should be selected based on the toxicity of individual cells, which is between 35-40%.

[0102] (5) Cell viability was tested at 48 and 72 hours after addition.

[0103] (6) Chemotherapy synergistic experiment of Astragalus extract (r-APS) and Astragalus extract and mannose pharmaceutical combination (r-APS+mannose).

[0104] (7) Inoculate cells into 96-well plates and incubate for 24 hours.

[0105] (8) Simultaneously administer Astragalus extract (r-APS) or Astragalus extract and mannose pharmaceutical combination (r-APS+mannose) and chemotherapeutic drugs for 48 hours. The doses of Astragalus extract (r-APS) and Astragalus extract and mannose pharmaceutical combination (r-APS+mannose) were selected as the three toxic doses for testing. Cell viability was measured by MTS after 48 hours.

[0106] The results of the toxic dose test are shown in Table 6. The chemotherapy drug olaparib, at 0.7M, can kill up to 60% of cancer cells, simulating the situation of cancer patients after taking chemotherapy drugs. Subsequent chemotherapy synergistic experiments were then conducted using astragalus extract (r-APS) and a combination of astragalus extract and mannose (r-APS+mannose). (Experimental results are shown in Figure 5A.)

[0107] Table 6. Cell survival rate (%) of ovarian cancer cell lines (OVCAR cells) killed by different concentrations of the chemotherapy drug olaparib.

[0108]

[0109]

[0110] The synergistic effects of Astragalus extract (r-APS) and the pharmaceutical composition of Astragalus extract and mannose (r-APS+mannose) on chemotherapy are shown in Table 7 below. After adding Astragalus extract (r-APS) to ovarian cancer cell lines (OVCAR cells) and culturing them for 48 hours, the results showed that using Astragalus extract (r-APS) alone actually promoted the growth of cancer cells, thus demonstrating that Astragalus extract (r-APS) alone had no significant toxic effect (as shown in Figure 5B).

[0111] Table 7. Cell viability (%) of ovarian cancer cell lines (OVCAR cells) after 48 hours of culture with different concentrations of Astragalus extract (r-APS)

[0112]

[0113]

[0114] As shown in Table 8, after culturing ovarian cancer cell lines (OVCAR cells) with a pharmaceutical composition of Astragalus extract and mannose (r-APS+mannose) for 48 hours, the results showed that the use of the pharmaceutical composition of Astragalus extract and mannose (r-APS+mannose) promoted the growth of cancer cells, thus showing that the use of the pharmaceutical composition of Astragalus extract and mannose (r-APS+mannose) alone had no significant toxic effect (as shown in Figure 5C).

[0115] Table 8. Cell viability (%) of ovarian cancer cell lines (OVCAR cells) after 48 hours of culture with different concentrations of Astragalus extract and mannose pharmaceutical composition (r-APS+mannose).

[0116]

[0117] As shown in Table 9, after culturing ovarian cancer cell lines (OVCAR cells) with 0.7M olaparib and r-APS for 48 hours, the results showed that the combination of r-APS and the chemotherapy drug olaparib effectively inhibited the survival rate of OVCAR cells. Therefore, the combination of r-APS and chemotherapy drugs has a significant toxic effect (as shown in Figure 5D).

[0118] Table 9. Cell viability (%) of ovarian cancer cell lines (OVCAR cells) cultured for 48 hours with 0.7M olaparib and r-APS extract.

[0119]

[0120] As shown in Table 10, after culturing ovarian cancer cell lines (OVCAR cells) with 0.7M olaparib and a combination of astragalus extract and mannose (r-APS+mannose) for 48 hours, the results showed that the combination of astragalus extract and mannose with chemotherapy drugs could effectively inhibit the survival rate of ovarian cancer cell lines (OVCAR cells). Therefore, the combination of astragalus extract and mannose with chemotherapy drugs has a significant toxic effect (as shown in Figure 5E).

[0121] Table 10. Cell viability (%) of ovarian cancer cell lines (OVCAR) cultured for 48 hours with a pharmaceutical composition of 0.7M olaparib, astragalus extract, and mannose (r-APS+mannose).

[0122]

[0123]

[0124] The results of this experiment show that the combination of Astragalus extract and mannose pharmaceutical composition of the present invention with chemotherapy drugs can further reduce the survival rate of colorectal cancer cells by 43% compared with the use of drugs alone, thus effectively enhancing the therapeutic effect of chemotherapy drugs.

[0125] In summary, the combination of Astragalus extract and mannose (r-APS+mannose) in this invention, when used in conjunction with chemotherapy drugs, can reduce cancer cell survival rate by at least 16%. Therefore, it can effectively enhance the ability of chemotherapy drugs to reduce cancer cell survival rate and also effectively inhibit tumor cell proliferation. Compared with the general use of Astragalus extract (r-APS) alone, it can achieve a stronger chemotherapy effect, and can maintain or enhance the therapeutic effect of chemotherapy drugs even in drug-resistant cancers.

[0126] All features disclosed in this invention can be implemented in any combination. Each feature disclosed in this invention can be replaced by a substitute for the same, equivalent, or similar purpose. Therefore, unless expressly specified, each disclosed feature is merely one embodiment of a kind of equivalent or similar feature.

Claims

1. Use of an Astragalus membranaceus medicinal composition in the preparation of a drug for enhancing the inhibitory effect of a cancer chemotherapy drug on the survival rate of cancer cells, characterized in that, The Astragalus membranaceus medicinal composition contains an Astragalus membranaceus extract and mannose.

2. The use according to claim 1, characterized in that, The cancer chemotherapy drug is a chemotherapy targeted drug, and the chemotherapy targeted drug is a chemotherapy targeted drug for the corresponding cancer type.

3. The use according to claim 1, characterized in that, The cancer includes colorectal cancer, ovarian cancer or lung cancer.

4. The use according to claim 2, characterized in that, The chemotherapy targeted drug for the corresponding cancer type includes Regorafenib, Olaparib or Tarceva.

5. The use according to claim 1, characterized in that, The effective dose ratio of the Astragalus membranaceus extract and the mannose is 1.5 - 4.5:5.5 - 8.5, and the concentration range of the Astragalus membranaceus extract and mannose composition is 0 - 10 mg / mL.

6. The use according to claim 1, characterized in that, The medicinal composition is a tablet, pill, granule, powder, capsule or liquid preparation.

7. Use of an Astragalus membranaceus medicinal composition in the preparation of a drug for enhancing the inhibitory effect of a cancer chemotherapy drug on the survival rate of cancer cells in the treatment of drug-resistant cancer, characterized in that, The Astragalus membranaceus medicinal composition contains an Astragalus membranaceus extract and mannose.

8. The use according to claim 7, characterized in that, The cancer chemotherapy drug is a chemotherapy targeted drug, and the chemotherapy targeted drug is a chemotherapy targeted drug for the corresponding cancer type.

9. The use according to claim 8, characterized in that, The chemotherapy targeted drug for the corresponding cancer type includes Regorafenib, Olaparib or Tarceva.

10. The use according to claim 7, characterized in that, The cancer is a solid tumor cancer.

11. The use according to claim 8, characterized in that, The solid tumor cancer includes colorectal cancer, ovarian cancer or lung cancer.

12. The use according to claim 7, characterized in that, The effective dose ratio of the Astragalus membranaceus extract and the mannose is 1.5 - 4.5:5.5 - 8.5, and the concentration range of the Astragalus membranaceus extract and mannose composition is 0 - 10 mg / mL.

13. Use of an Astragalus membranaceus medicinal composition in the preparation of a drug for enhancing the inhibitory effect of a cancer chemotherapy drug on the proliferation of tumor cells, characterized in that, The Astragalus membranaceus medicinal composition contains an Astragalus membranaceus extract and mannose.

14. The use according to claim 13, characterized in that, The tumor cells are drug-resistant tumor cells.

15. The use according to claim 13, characterized in that, The cancer chemotherapy drug is a chemotherapy targeted drug, and the chemotherapy targeted drug is a chemotherapy targeted drug for the corresponding cancer type.

16. The use according to claim 15, characterized in that, The chemotherapy targeted drug for the corresponding cancer type includes Regorafenib, Olaparib or Tarceva.

17. The use according to claim 13, characterized in that, The tumor cells include colorectal cancer, ovarian cancer or lung cancer.

18. The use according to claim 13, characterized in that, The effective dose ratio of the Astragalus membranaceus extract and the mannose is 1.5 - 4.5:5.5 - 8.5, and the concentration range of the Astragalus membranaceus extract and mannose composition is 0 - 10 mg / mL.